---
{"dg-publish":true,"permalink":"/usmle/immunology/transplant-rejection/"}
---


| Feature            | Hyperacute Rejection                                         | Acute Rejection                                                                                      | Chronic Rejection                                                    | Graft-vs-Host Disease (GVHD)                                                                                       |
| ------------------ | ------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------ |
| **Onset**          | Mins-Hrs                                                     | Wks-Months (typ <3mo-1yr)                                                                            | Months-Yrs                                                           | Variable (Acute <100d, Chronic >100d)                                                                              |
| **Patho/Etiology** | Pre-formed Ab (Type II HSR); Thrombosis                      | Cell-mediated (T-cell vs donor MHC; [[USMLE/Immunology/Type IV hypersensitivity reaction\|Type IV HSR]]) &/or humoral | Chronic inflammation, fibrosis, atrophy; Complex                     | Donor T-cells attack recipient tissues                                                                             |
| **Presentation**   | Immediate graft failure, mottling, cyanosis                  | Graft dysfunction (e.g., ↑Cr, ↑LFTs), fever, tenderness                                              | Gradual loss of fxn; Organ-specific sx                               | **Acute:** Rash, GI ([[USMLE/GI/Diarrhea\|diarrhea]]), Liver (jaundice). **Chronic:** Skin (sclerosis, lichenoid), sicca, multi-organ |
| **Diagnosis**      | Clinical (intra-op); Bx: thrombosis/necrosis                 | Bx: Cellular infiltrate, endothelialitis                                                             | Bx: Fibrosis, [[USMLE/Cardiology/Atherosclerosis\|arteriosclerosis]] (e.g., VOD, BOS) | Clinical; Bx of affected organ (skin, GI)                                                                          |
| **Mgmt/Tx**        | Irreversible; Graft removal                                  | Immunosuppression ([[USMLE/Pharmacology/Corticosteroids\|steroids]], anti-[[USMLE/Blood/Lymphocyte\|lymphocyte]] Ab)                            | Poorly responsive; Optimize IS; Re-transplant                        | Immunosuppression ([[USMLE/Pharmacology/Corticosteroids\|steroids]]); Supportive                                                      |
| **Key Assoc.**     | ABO/[[USMLE/Immunology/HLA system\|HLA]] incompatibility; Prior sensitization | Most common type                                                                                     | Major cause of late graft loss                                       | Allogeneic HSCT; Donor cells attack host                                                                           |
| **Buzzword**       | **Pre-formed antibodies**                                    | **T-cell mediated against graft**                                                                    | **Fibrosis, insidious loss of function**                             | **Donor [[USMLE/Blood/Lymphocyte\|lymphocytes]] attack recipient**                                                             |
# Pathophysiology
## Hyperacute rejection
- <span style="background:rgba(240, 200, 0, 0.2)">Humoral rejection (type II hypersensitivity reaction)</span>: recipient's <span style="background:rgba(240, 200, 0, 0.2)">preformed cytotoxic antibodies against donor's class I [[USMLE/Immunology/HLA system\|HLA]] molecules or blood group antigens </span>�?activation of the [[USMLE/Immunology/Complement system\|complement system]] and adhesion to cells �?<span style="background:rgba(240, 200, 0, 0.2)">thrombosis of vessels �?graft ischemia and necrosis</span>
- Preformed antibodies against [[USMLE/Immunology/HLA system\|HLA]] antigens result from exposure to foreign [[USMLE/Immunology/HLA system\|HLA]] haplotypes during [[USMLE/Reproductive/Pregnancy\|pregnancy]], [[USMLE/Blood/Transfusion\|transfusion]], or a previously rejected transplant.
## Acute rejection
- Allorecognition �?T [[USMLE/Blood/Lymphocyte\|lymphocyte]] induced cell-mediated and/or humoral immunity
- <span style="background:rgba(240, 200, 0, 0.2)">Acute cellular rejection ([[USMLE/Immunology/Type IV hypersensitivity reaction\|type IV hypersensitivity reaction]])</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Donor MHC class II antigens react with recipient CD4+ T cells</span>, which then differentiate into Th1 helper T cells �?cytokine (INF-γ) release �?macrophage recruitment �?parenchymal and endothelial inflammation
	- <span style="background:rgba(240, 200, 0, 0.2)">Donor MHC class I antigens react with recipient CD8+ T cells</span> �?direct cytotoxic cell damage
- Acute humoral rejection (type II hypersensitivity reaction): recipient antibodies, formed before or after transplantation, react against donor [[USMLE/Immunology/HLA system\|HLA]] antigens
## Chronic rejection
- <span style="background:rgba(240, 200, 0, 0.2)">Combination of humoral rejection (type II hypersensitivity reaction) and cellular rejection ([[USMLE/Immunology/Type IV hypersensitivity reaction\|type IV hypersensitivity reaction]])</span>
- Donor MHC class II antigens react with recipient CD4+ T cells �?differentiation into Th1 helper T cells �?cytokine (INF-γ) release �?macrophage recruitment �?<span style="background:rgba(240, 200, 0, 0.2)">parenchymal and endothelial inflammation</span>
# Graft-versus-host disease
---
## Etiology
- Graft-versus-host disease (GvHD) is common in <span style="background:rgba(240, 200, 0, 0.2)">transplantation of lymphocyte-rich organs</span>, including:
	- <span style="background:rgba(240, 200, 0, 0.2)">Allogeneic hematopoietic stem cell transplantation </span>
	- Transfusion of nonirradiated blood products
- HLA mismatch (especially HLA-A, HLA-B, and HLA-DR) is associated with an increased risk of GvHD.

